CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that Al Shalan, Cerus’ exclusive distributor for Saudi Arabia, has signed a three-year agreement with the King Faisal Specialist Hospital, a leading medical center in Saudi Arabia, to supply the INTERCEPT Blood System for platelets. This contract allows for the routine use of INTERCEPT to treat up to 100% of the hospital’s platelet production of approximately 5,600 units annually.
